Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Giant Cell Arteritis
NCT02955147Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2016
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ustekinumab in giant cell arteritis (GCA), sponsored by Massachusetts General Hospital. Primary endpoint: Percentage of Patients in Glucocorticoid-free Remission at 52 weeks. Started Dec 2016; status: terminated.
02
Drugs
ustekinumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT02955147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955147.